Insights That

Move You Forward

Helping you make smarter decisions, avoid costly missteps, and
bring safe, effective products to market with confidence

What Happens After Clinical Trial Close-Out: Transitioning to Reimbursement

What Happens After Clinical Trial Close-Out: Transitioning to Reimbursement

Clinical trial close-out is no longer the end of the development process. In 2026, sponsors must transition quickly from regulatory evidence generation to reimbursement and market access planning. Learn how clinical strategy, real-world evidence, payer expectations, and post-market planning now shape commercialization success for medical devices and combination products.

Read More
Trying to Keep Up in April

Trying to Keep Up in April

April’s Trying to Keep Up episodes covered FDA shifts, clinical strategy decisions, and the realities of working in MedTech right now. This recap breaks down the key takeaways, what they mean for your team, and includes a full roundup of the podcast’s now-signature intro jokes.

Read More
Navigating the FDA During a Government Shutdown

Navigating the FDA During a Government Shutdown

When the U.S. government shuts down, FDA operations slow—and medical device companies can face costly delays. In this Global Medical Device Podcast Q&A, NMCG President and former FDA Scientific Reviewer Michael Nilo explains what continues, what stops, and how MedTech leaders can strategically navigate the disruption.

Read More